source
- Roche’s CEO has ‘absolutely not’ changed tune on Poseida despite scrapping CAR-T from the buyoutRoche’s CEO has insisted to Fierce that the company’s view on its $1.5 billion Poseida buyout has “absolutely not” changed, even as the Swiss pharma scraps one of the CAR-T therapy’s from the acqui…Fierce Biotech · 4h ago↗ source
- GSK and Ionis receive FDA nod for hepatitis B therapy promising functional cureGSK and Ionis announced that the U.S. Food and Drug Administration has approved their hepatitis B drug bepirovirsen, now marketed as Hibsago. The therapy is intended for chronic hepatitis B patien…